The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy

被引：98

作者：

Zheng, Xiangjin ^{[1
,2
,3
]}

Li, Wan ^{[1
,2
,3
]}

Ren, Liwen ^{[1
,2
,3
]}

Liu, Jinyi ^{[2
,3
]}

Pang, Xiaocong ^{[2
,3
]}

Chen, Xiuping ^{[4
]}

Kang, De ^{[2
,3
]}

Wang, Jinhua ^{[1
,2
,3
]}

Du, Guanhua ^{[1
,2
,3
]}

机构：

[1] State Key Lab Bioact Subst & Funct Nat Med, Beijing, Peoples R China

[2] Chinese Acad Med Sci, Inst Mat Med, Key Lab Drug Target Res & Drug Screen, Beijing 100050, Peoples R China

[3] Peking Union Med Coll, Beijing 100050, Peoples R China

[4] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau, Peoples R China

来源：

PHARMACOLOGY & THERAPEUTICS | 2019年 / 195卷

基金：

中国国家自然科学基金;

关键词：

Sphingosine kinase 1; Cancer; Mechanism; Inhibitor; PROTEIN-KINASE-C; HEPATOCELLULAR-CARCINOMA CELLS; FTY720 INDUCES APOPTOSIS; UP-REGULATION; INHIBITOR; FUNCTIONAL-CHARACTERIZATION; SPHINGOLIPID RHEOSTAT; PANCREATIC-CANCER; MOLECULAR-CLONING; MULTIPLE-MYELOMA;

D O I：

10.1016/j.pharmthera.2018.10.011

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sphingolipid metabolites, such as ceramide, sphingosine and sphingosine-1-phosphate (SIP), play many important roles in cellular activities. Ceramide and sphingosine inhibit cell proliferation and induce cell apoptosis while SIP has the opposite effect. Maintaining a metabolic balance of sphingolipids is essential for growth and development of cells. Sphingosine kinase (SPHK) is an important regulator for keeping this balance. It controls the level of SIP and plays important roles in proliferation, migration, and invasion of cancer cells and tumor angiogenesis. There are two isoenzymes of sphingosine kinase, SPHK1 and SPHK2. SPHK1 is ubiquitously expressed in most cancers where it promotes survival and proliferation, while SPHK2 is restricted to only certain tissues and its functions are not well characterized. SPHK1 is currently considered as a novel target for the treatment of cancers. Targeting SPHK1 would provide new strategies for cancer treatment and improve the prognosis of cancer patients. Here we review and summarize the current research findings on the SPHK1-S1P axis in cancer from many aspects including structure, expression, regulation, mechanism, and potential inhibitors. (C) 2018 Elsevier Inc. All rights reserved.

引用

页码：85 / 99

页数：15

共 141 条

[81] Regulation of sphingosine kinase 1 gene expression by protein kinase C in a human leukemia cell line, MEG-O1 [J].

Nakade, Y ;

Banno, Y ;

T-Koizumi, K ;

Hagiwara, K ;

Sobue, S ;

Koda, M ;

Suzuki, M ;

Kojima, T ;

Takagi, A ;

Asano, H ;

Nozawa, Y ;

Murate, T .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2003, 1635 (2-3) :104-116

[82] Sphingosine Kinase Isoforms Regulate Oxaliplatin Sensitivity of Human Colon Cancer Cells through Ceramide Accumulation and Akt Activation [J].

Nemoto, Satoshi ;

Nakamura, Mitsuhiro ;

Osawa, Yosuke ;

Kono, Saki ;

Itoh, Yoshinori ;

Okano, Yukio ;

Murate, Takashi ;

Hara, Akira ;

Ueda, Hiroshi ;

Nozawa, Yoshinori ;

Banno, Yoshiko .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (16) :10422-10432

[83] Revisiting the sphingolipid rheostat: Evolving concepts in cancer therapy [J].

Newton, Jason ;

Lima, Santiago ;

Maceyka, Michael ;

Spiegel, Sarah .

EXPERIMENTAL CELL RESEARCH, 2015, 333 (02) :195-200

[84] Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer [J].

Ohotski, J. ;

Long, J. S. ;

Orange, C. ;

Elsberger, B. ;

Mallon, E. ;

Doughty, J. ;

Pyne, S. ;

Pyne, N. J. ;

Edwards, J. .

BRITISH JOURNAL OF CANCER, 2012, 106 (08) :1453-1459

[85] Purification and characterization of rat kidney sphingosine kinase [J].

Olivera, A ;

Kohama, T ;

Tu, ZX ;

Milstien, S ;

Spiegel, S .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (20) :12576-12583

[86] Sphingosine-1-phosphate lyase potentiates apoptosis via p53-and p38-dependent pathways and is down-regulated in colon cancer [J].

Oskouian, Babak ;

Sooriyakumaran, Prathap ;

Borowsky, Alexander D. ;

Crans, Angelina ;

Dillard-Telm, Lisa ;

Tam, Yuen Yee ;

Bandhuvula, Padmavathi ;

Saba, Julie D. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (46) :17384-17389

[87] A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia [J].

Paugh, Steven W. ;

Paugh, Barbara S. ;

Rahmani, Mohamed ;

Kapitonov, Dmitri ;

Almenara, Jorge A. ;

Kordula, Tomasz ;

Milstien, Sheldon ;

Adams, Jeffrey K. ;

Zipkin, Robert E. ;

Grant, Steven ;

Spiegel, Sarah .

BLOOD, 2008, 112 (04) :1382-1391

[88] Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models [J].

Pchejetski, Dimitri ;

Doumerc, Nicolas ;

Golzio, Muriel ;

Naymark, Maria ;

Teissie, Justin ;

Kohama, Takafumi ;

Waxman, Jonathan ;

Malavaud, Bernard ;

Cuvillier, Olivier .

MOLECULAR CANCER THERAPEUTICS, 2008, 7 (07) :1836-1845

[89] A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties [J].

Pitman, Melissa R. ;

Powell, Jason A. ;

Coolen, Carl ;

Moretti, Paul A. B. ;

Zebol, Julia R. ;

Pham, Duyen H. ;

Finnie, John W. ;

Don, Anthony S. ;

Ebert, Lisa M. ;

Bonder, Claudine S. ;

Gliddon, Briony L. ;

Pitson, Stuart M. .

ONCOTARGET, 2015, 6 (09) :7065-7083

[90] Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation [J].

Pitson, SM ;

Moretti, PAB ;

Zebol, JR ;

Lynn, HE ;

Xia, P ;

Vadas, MA ;

Wattenberg, BW .

EMBO JOURNAL, 2003, 22 (20) :5491-5500

← 4 5 6 7 8 9 10 11 12 13 →